as of 11-18-2026 10:24am EST
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 1.1B | IPO Year: | 2018 |
| Target Price: | $26.78 | AVG Volume (30 days): | 876.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -0.27 | EPS Growth: | 41.33 |
| 52 Week Low/High: | $11.48 - $25.92 | Next Earning Date: | 11-02-2026 |
| Revenue: | $67,301,000 | Revenue Growth: | 21.53% |
| Revenue Growth (this year): | 15.53% | Revenue Growth (next year): | 15.50% |
| P/E Ratio: | -85.70 | Index: | |
| Free Cash Flow: | -9089000.0 | FCF Growth: | N/A |
Chief Op & Financial Officer
Avg Cost/Share
$25.00
Shares
3,247
Total Value
$81,175.00
Owned After
211,250
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$25.30
Shares
75,000
Total Value
$1,897,642.50
Owned After
304,256
SEC Form 4
SVP, Ops & Adm/Chief Legal Ofr
Avg Cost/Share
$24.80
Shares
36,241
Total Value
$898,802.17
Owned After
40,167
SEC Form 4
Director
Avg Cost/Share
$20.89
Shares
20,000
Total Value
$417,820.00
Owned After
16,057
SEC Form 4
Chief Op & Financial Officer
Avg Cost/Share
$22.50
Shares
3,738
Total Value
$84,105.00
Owned After
211,250
SEC Form 4
SVP, Ops & Adm/Chief Legal Ofr
Avg Cost/Share
$22.11
Shares
29,665
Total Value
$655,744.83
Owned After
40,167
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$20.05
Shares
38,006
Total Value
$762,012.70
Owned After
304,256
SEC Form 4
Chief Op & Financial Officer
Avg Cost/Share
$19.50
Shares
1,731
Total Value
$33,754.50
Owned After
211,250
SEC Form 4
Chief Op & Financial Officer
Avg Cost/Share
$18.18
Shares
3,318
Total Value
$60,324.97
Owned After
211,250
SVP, Ops & Adm/Chief Legal Ofr
Avg Cost/Share
$18.16
Shares
3,133
Total Value
$56,918.15
Owned After
40,167
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Maheshwari Anshul | SIBN | Chief Op & Financial Officer | Nov 4, 2026 | Sell | $25.00 | 3,247 | $81,175.00 | 211,250 | |
| FRANCIS LAURA | SIBN | Chief Executive Officer | Nov 4, 2026 | Sell | $25.30 | 75,000 | $1,897,642.50 | 304,256 | |
| Pisetsky Michael A | SIBN | SVP, Ops & Adm/Chief Legal Ofr | Nov 4, 2026 | Sell | $24.80 | 36,241 | $898,802.17 | 40,167 | |
| DUNN JEFFREY W | SIBN | Director | Nov 2, 2026 | Sell | $20.89 | 20,000 | $417,820.00 | 16,057 | |
| Maheshwari Anshul | SIBN | Chief Op & Financial Officer | Oct 29, 2026 | Sell | $22.50 | 3,738 | $84,105.00 | 211,250 | |
| Pisetsky Michael A | SIBN | SVP, Ops & Adm/Chief Legal Ofr | Oct 29, 2026 | Sell | $22.11 | 29,665 | $655,744.83 | 40,167 | |
| FRANCIS LAURA | SIBN | Chief Executive Officer | Oct 12, 2026 | Sell | $20.05 | 38,006 | $762,012.70 | 304,256 | |
| Maheshwari Anshul | SIBN | Chief Op & Financial Officer | Oct 5, 2026 | Sell | $19.50 | 1,731 | $33,754.50 | 211,250 | |
| Maheshwari Anshul | SIBN | Chief Op & Financial Officer | Oct 2, 2026 | Sell | $18.18 | 3,318 | $60,324.97 | 211,250 | |
| Pisetsky Michael A | SIBN | SVP, Ops & Adm/Chief Legal Ofr | Oct 2, 2026 | Sell | $18.16 | 3,133 | $56,918.15 | 40,167 |
SEC 8-K filings with transcript text
Nov 2, 2026 · 100% conf.
1D
-7.18%
$18.88
Act: +8.06%
5D
-10.56%
$18.20
20D
-8.42%
$18.63
2 exhibit991_q326earningsrel.htm
Document
Exhibit 99.1
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
Delivered ~20% U.S. procedure volume growth in the third quarter
Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period)
•Worldwide revenue of $55.7 million, representing growth of 14.5%
•U.S. revenue of $52.8 million, representing growth of 13.9%
•Gross margin of 79.3%
•Net loss of $3.6 million, representing an improvement of 20.7%
•Positive adjusted EBITDA of $3.0 million, representing an improvement of 32.4%
•Positive cash from operations of $5.9 million, representing an improvement of 154.4%
•$146.3 million in cash and equivalents
Recent Operational Highlights (any comparisons are to the prior year period)
•1,770 active U.S. physicians, representing growth of ~16%
•In September, received 510(k) clearance for iFuse Granite Onyx, a FDA breakthrough device targeting failures in spine fusion procedures, with an estimated total addressable market of ~$1.5 billion annually
•In October, new MS-DRGs took effect for complex spinal fusion procedures incorporating iFuse Bedrock Granite, increasing average hospital inpatient payments by up to ~$50,000 per qualifying procedure
SAN JOSE, Calif., November 2, 2026 - SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended September 30, 2026.
“Robust third-quarter growth in procedure volumes and active physicians underscores rising demand for our diversified and differentiated platform technologies,” said Laura Francis, Chief Executive Officer. “We enter the fourth quarter with a record number of active physicians, favorable DRG changes and exceptional early uptake in our alpha launch of iFuse Granite Onyx, our new platform technology that expands our estimated total addressable market to approximately $5 billion. These drivers position us for an excellent finish to 2026 and enter 2027 with the strongest foundation for growth acceleration in our company's history.”
Third Quarter 2026 Financial Results
Worldwide revenue was $55.7 million in the third quarter 2026, a 14.5% increase from $48.7 million in the corresponding period in 2025. U.S. revenue for the third quarter 2026 was $52.8 million, a 13.9% increase from $46.4 million in the corresponding period in 2025. U.S. revenue growth benefited from approximately 19.5% growth in procedure volume partially offset by lower average selling price due to procedure mix and the growing interventional spine physician demand for the INTRA platform in the office-based and ASC sites of care. International revenue for the third quarter 2026 was $2.9 million, a 27.0% increase from $2.3 million in the corresponding period in 2025. International revenue growth reflects the increasing adoption of iFuse TORQ and iFuse TORQ TNT.
Gross profit was $44.2 million in the third quarter 2026, an increase of 13.7% from $38.8 million in the corresponding period in 2025. Gross margin was 79.3% for the third quarter 2026, compared to 79.8% in the corresponding period in 2025 driven by procedure and site of care mix.
Operating expenses increased 9.7% to $48.5 million in the third quarter 2026, as compared to $44.2 million in the corresponding period in 2025. The increase was primarily driven by higher sales commissions on increased revenue, marketing to support new product launches and continued investment in research and development.
Operating loss improved by 19.2% to $4.4 million in the third quarter 2026, as compared to an operating loss of $5.4 million in the corresponding period in 2025.
Net loss improved by 20.7% to $3.6 million, or $0.08 per diluted share, in the third quarter 2026, as compared to a net loss of $4.6 million, or $0.11 per diluted share, in the corresponding period in 2025.
Adjusted EBITDA was $3.0 million in the third quarter 2026, improving from an adjusted EBITDA of $2.3 million in the corresponding period in 2025.
Cash and equivalents as of September 30, 2026 were $146.3 million, compared to $145.9 million as of June 30, 2026. Net cash generated was $0.4 million in the third quarter 2026, compared to $0.2 million in net cash generated during the corresponding period in 2025.
Updated Fiscal 2026 Outlook
SI-BONE reaffirms its previously issued 2026 worldwide revenue and gross margin guidance. Based on year to date operating expense trend the Company is reducing the operating expense growth expectation to 10.5%.
Fiscal Year 2026 Guidance
Updated (November 2, 2026)Prior (August 3, 2026)
Revenue
~15-16% growth
~15-16% growth
Gross Margin~79.0%~79.0%
Operating Expenses ~10.5% growth
at revenue midpoint
~12.0% growth
at revenue midpoint
Adjusted EBITDA Positive
Positive
Webcast Information
SI-BONE will host a confer
Aug 3, 2026 · 86% conf.
1D
-6.68%
$17.22
Act: -0.05%
5D
-9.83%
$16.64
Act: +2.11%
20D
-7.84%
$17.00
2 exhibit991_q226earningsrel.htm
Document
Exhibit 99.1
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA
~19% increase in U.S. physician base
Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period)
•Worldwide revenue of $56.0 million, representing growth of 15.2%
•U.S. revenue of $53.2 million, representing growth of 14.7%
•Gross margin of 79.5%
•Net loss of $4.1 million, representing an improvement of 33.6%
•Positive adjusted EBITDA of $2.8 million, representing an improvement of 178.0%
•Positive cash from operations of $0.8 million
•$145.9 million in cash and equivalents, representing a sequential increase of $1.3 million
Recent Operational Highlights (any comparisons are to the prior year period)
•1,715 active U.S. physicians, representing growth of 19%
•$2.2 million in trailing 12-month average revenue per territory, representing an increase of 5%
•In June, submitted 510(k) application for the third-breakthrough device targeting one of the largest unmet needs in spine surgery
•CMS finalized new MS-DRG family providing higher payments for complex spinal fusion procedures that incorporate iFuse Bedrock Granite in an in-patient setting, effective October 1
SANTA CLARA, Calif. August 3, 2026 - SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended June 30, 2026.
“Our accelerating growth and expanding profitability reinforces our conviction in the demand for our superior platform technologies and the significant runway ahead,” said Laura Francis, Chief Executive Officer. “This quarter’s record physician engagement reflects our strategy to develop unique procedural solutions for patients with compromised bone and underscores the meaningful market need we are addressing. We are excited about the
upcoming third breakthrough device launch in the fourth quarter, a substantially improved reimbursement backdrop, and an expanding commercial reach. Together, these tailwinds position us to expand adoption, broaden patient access, and enter our next phase of strong, sustainable multi-year revenue growth.”
Second Quarter 2026 Financial Results
Worldwide revenue was $56.0 million in the second quarter 2026, a 15.2% increase from $48.6 million in the corresponding period in 2025. U.S. revenue for the second quarter 2026 was $53.2 million, a 14.7% increase from $46.4 million in the corresponding period in 2025. U.S. revenue growth benefited from 14.9% growth in procedure volume. International revenue for the second quarter 2026 was $2.8 million, a 25.9% increase from $2.2 million in the corresponding period in 2025. International revenue growth reflects the strong initial reception for iFuse TORQ and iFuse TORQ TNT.
Gross profit was $44.5 million in the second quarter 2026, an increase of 14.8% from $38.8 million in the corresponding period in 2025. Gross margin was 79.5% for the second quarter 2026, compared to 79.8% in the corresponding period in 2025.
Operating expenses increased 7.7% to $49.4 million in the second quarter 2026, as compared to $45.8 million in the corresponding period in 2025. The change in operating expenses was primarily driven by general commercial activity related to higher revenue and new product rollout as well as increase in research and development spend.
Operating loss improved by 31.4% to $4.8 million in the second quarter 2026, as compared to an operating loss of $7.0 million in the corresponding period in 2025.
Net loss improved by 33.6% to $4.1 million, or $0.09 per diluted share, in the second quarter 2026, as compared to a net loss of $6.2 million, or $0.14 per diluted share, in the corresponding period in 2025.
Adjusted EBITDA was $2.8 million in the second quarter 2026, improving from an adjusted EBITDA of $1.0 million in the corresponding period in 2025.
Cash and equivalents as of June 30, 2026 were $145.9 million, compared to $144.7 million as of March 31, 2026. Net cash generated was $1.3 million in the second quarter 2026, compared to $1.1 million in net cash generated during the corresponding period in 2025.
Updated Fiscal 2026 Financial Guidance
SI-BONE increases 2026 worldwide revenue to be in the range of $231 million to $233 million, implying year-over-year growth of ~15% to 16%. The Company is maintaining gross margin guidance at ~79%, and updating operating expenses guidance to now be ~12% compared to the prior guidance of ~12.5%.
Fiscal Year 2026 Guidance
New (August 3, 2026)Prior (May 11, 2026)
Revenue
~15-16% growth
~14%-16% growth
Gross Margin~79.0%~79.0%
Operating Expenses ~12.0% growth
at revenue midpoint
~12.5% growth
at revenue midpoint
Adjusted EBITDA Positive
Positive
Webcast Information
S
May 11, 2026 · 100% conf.
1D
+4.67%
$12.15
Act: +19.72%
5D
+8.14%
$12.56
Act: +27.13%
20D
+5.67%
$12.27
Act: +33.76%
2 exhibit991_q126earningsrel.htm
Document
Exhibit 99.1
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA
First Quarter 2026 Financial Highlights (all comparisons are to the prior year period)
•Worldwide revenue of $52.6 million, representing growth of 11.2%
•U.S. revenue of $49.3 million, representing growth of 10.0%
•Gross margin of 79.8%
•Net loss of $4.3 million, representing an improvement of 33.8%
•Adjusted EBITDA of $2.5 million, representing an improvement of over 440%
•$144.7 million in cash and equivalents
Recent Operational Highlights (any comparisons are to the prior year period)
•Over 1,650 active U.S. physicians, representing growth of 17%
•$2.2 million in trailing 12-month average revenue per territory, representing an increase of 11%
•Expanded international presence with the launch of iFuse TORQ TNT in Europe and iFuse TORQ in Australia
•CMS proposes, in their FY2027 IPPS Proposed Rule, the creation of a new MS-DRG family with higher payment for hospitals supporting complex spinal fusion procedures that incorporate iFuse Bedrock Granite
SANTA CLARA, Calif. May 11, 2026 - SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended March 31, 2026.
"The first quarter demonstrated the strength and durability of our platform, with record physician engagement and double-digit growth across all key metrics," said Laura Francis, Chief Executive Officer. "We advanced several high-impact initiatives during the quarter, including the U.S. launch of INTRA Ti, our trauma partnership with Smith + Nephew, and the introduction of iFuse TORQ TNT and iFuse TORQ across various international markets, each of which expands our addressable market and deepens our competitive position. With growing commercial scale and our third breakthrough device on track for launch later this year, we are well positioned to accelerate revenue growth through 2026 and into 2027."
First Quarter 2026 Financial Results
Worldwide revenue was $52.6 million in the first quarter 2026, a 11.2% increase from $47.3 million in the corresponding period in 2025. U.S. revenue for the first quarter 2026 was $49.3 million, a 10.0% increase from $44.8 million in the corresponding period in 2025. U.S revenue growth benefited from expanded adoption of the product portfolio across all sites of care and increased sales channel coverage. International revenue for the first quarter 2026 was $3.3 million, a 33.9% increase from $2.5 million in the corresponding period in 2025. International revenue growth reflects the growing demand for iFuse TORQ.
Gross profit was $41.9 million in the first quarter 2026, an increase of 11.3% from $37.7 million in the corresponding period in 2025. Gross margin in the first quarter 2026 was stable compared to the prior year period at 79.8%.
Operating expenses increased 4.1% to $47.0 million in the first quarter 2026, as compared to $45.2 million in the corresponding period in 2025. The change in operating expenses was primarily driven by general commercial activity related to higher revenue and new product rollout.
Operating loss improved by 31.9% to $5.1 million in the first quarter 2026, as compared to an operating loss of $7.5 million in the corresponding period in 2025.
Net loss improved by 33.8% to $4.3 million, or $0.10 per diluted share, in the first quarter 2026, as compared to a net loss of $6.5 million, or $0.15 per diluted share, in the corresponding period in 2025.
Adjusted EBITDA was $2.5 million in the first quarter 2026, improving from an adjusted EBITDA of $0.5 million in the corresponding period in 2025.
Cash and equivalents as of March 31, 2026 were $144.7 million, compared to $147.8 million as of December 31, 2025.
Updated Fiscal 2026 Financial Guidance
SI-BONE increased 2026 worldwide revenue expectation to be in the range of $230 million to $233 million, implying year-over-year growth of ~14% to 16%. SI-BONE increased its estimate for full year 2026 gross margin to ~79%.
Fiscal Year 2026 Guidance
New (May 11, 2026)
Prior (February 23, 2026)
Revenue
~14-16% growth
~14%-16% growth
Gross Margin ~79.0% ~78.0%
Operating Expenses ~12.5% growth
at revenue midpoint
~12.5% growth
at revenue midpoint
Adjusted EBITDA Positive
Positive
Webcast Information
SI-BONE will host a conference call to discuss the first quarter 2026 financial results after market close on Monday, May 11, 2026 at 4:30 P.M. Eastern Time. The conference call can be accessed live over webcast at https://edge.media-server.com/mmc/p/vde24u4q. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The w
See how SIBN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "SIBN SI-BONE Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.